Full Spectrum Genetics deal

Full Spectrum announced it received a milestone payment from an undisclosed pharma under a 2012 deal to engineer and analyze variants of specified molecules using Full Spectrum's MapEng platform. The payment was triggered by the completion of the first project of generating multiple therapeutic protein and antibody candidates. The pharma has worldwide rights to any products arising from the deal. Full Spectrum said it has received multiple payments and may be eligible for more. The company declined to disclose details. ...